albert bourla. the ceo. welcome to mad money. >> hello. good to see you. >> you beat the numbers.with paxlovid. what do you say about the idea of what the mosaic is that gave you the beat or not? >> i would like to say there is no truth what they are saying. paxlovid is one of the drivers but it was a beat across the board. we beat the covered business and the non-covid business. we had growth of 14% we also had probably -- product launches. we beat the rsv vaccine. we beat newer tech which i know is very high in your heart. we beat the two inhibitors and we beat in oncology the new introduction to multiple myeloma. i think it was big across the board and people should focus on that. >> i think what happened is it might be across purposes. you see things that you like. i see things that i like. if this is the beginning there is so much more. maybe you should tell people, give us a little bit of a snapshot of what could be coming down the pipe because seagen is still early in the transition. >> those products are doing better collectively then what they will do -- a lot of that com

albert bourla."tarboard goes on to say, jeff smith, "while we cannot be certain the board did not authorize this behavior, we sincerely hope that all or at least some members of the board were wholly unaware of this coercive conduct, which in our view constitutes a clear breach of fiduciary duty." . it was interesting, the presence of d'amelio and read to begin with, and i know it enraged certain directions at pfizer, not to mention mr. bourla, the presence, in any way, their association with an activist investor, even if it was by a casual association, described here in the letter as having been approached and sharing their desire to see pfizer pursue a better path forward. >> this is astounding. first, it was astounding that read and d'amelio were going to go away. he was there november 2021. praised dr. bourla to me. said he was great. >> cfo of this company for all these years. >> i know, i mean, 15 years, and then you get what is -- i mean, if this is true, that these two people were threatened,

the current leadership under albert bourla has stepped away from the disciplined cost structure of novelrugs. >>> the wall street journal reporting that shein founder and ceo is heading to the u.s. this week meeting with investors ahead of the ipo in london. the investor says it is meeting with investors before heading across the atlantic. the heameetings will be the fir chance to meet with him. >>> shares of nintendo reporting on the report that the saudi investment fund is considering raising its stake in the company. i guess they want to play. the vaice chair of the fund telling media the fund is not in a rush to increase the stakes, but the offer would be in a friendly way. it owns 8.5% of nintendo shares. frank, i guess they're into games. >> thank you, bertha coombs. >>> and coming up, ubisoft breaks its science on a takeover. >>> and cnbc is celebrating hispanic heritage this month. as we head to break, here is the ceo of peloton. >> i'm first gen born in the united states. i think about the times when they, my parents were teaching themselves english and showing up in spaces and

albert bourla, ceo.zer has not done anything for ages even after he got aliens of dollars for the covid winfall. the management has blown way too much money just on failed acquisitions, underperforming. expensive acquisitions like the purchase of see jen. they -- star board, approached the former cfo and a fabulous one by the way. they both agreed to help because the current underperformance is so severe that they are upset. i think that is extraordinary. he was there guy. they want real change. not to mention better monetization of reason acquisitions. star board's investment does not mean all that much but it is serious business and very hard for the board of directors to ignore. it is true that they did misjudge how much money would be coming from the covid business, but i like the acquisition. the company has some novel treatments for hard to cure cancers. corporate boards are now hearing what they are saying. they are even getting restless themselves. i think it is about time. it is good news for sh

. >>> the ceo albert bourla will be at 6:00 p.m.astern. >>> the final name here is ford, which topped third quarter estimates when it reported earnings yesterday. but it also guyed on the low end of its previously-announced full-year earnings forecast range. phil lebeau has the story on ford. phil? >> yeah. rough day for ford, dom. when you take a look at shares down more than 8%, it's about the guidance. it changed in just three months. back in july, they said look, we expect to earn 10 to $12 billion this year. yesterday they said, well, it's going to be about 10 billion, which had been more than a few analysts saying, wait a second, what happened to 10 to 12, now it's 10? that's the primary reason why the stock is under pressure. there's also the issue of warranty cost. they believe they're making progress here. they didn't detail it and talk about it at great length yesterday, though it's still too high. they said it's too high. finally, there's higher inventory. though that is an issue that ford believes should move down. shoul

the current leadership under ceo albert bourla has stepped away from the disciplined cost structure inovel drugs. a pfizer spokesperson declined to comment on speculation of the rumor. there's no doubt. >> companies are very hard for activists to do well in in terms of very few financial engineering things you can do with the drug company. >> if you haven't invested in new drugs and all your bets on covid and the response of covid and vaccine for covid. >> the other things. >> where is the weight close? >> they failed on the weight loss. it didn't work. they invested heavily in cancer drugs and they're still two or three or four or five years out from knowing if it will work. the reason i say it is complicated to see an activist in a drugmaker to make a drugmaker successful. you need to make investments. it is not dividends back to shareholders or breaking companies up or doing something. you actually have -- this is an operational story and typically with a pharmaceutical company, it is a long term story. you cannot right the ship in two years. >> i remember when nelson peltz was appr

there was covid and you have to give albert bourla and pfizer credit for moving fast, spending big, savingg it. >> having an enormous piggy bank with which to spend, which they did quite aggressively. they should have because you want to diversify away from some of your core franchises. use it as an opportunity to do so. in this case it would appear to the extent there will be pressure on the cost structure and perhaps as well on succession for mr. bourla. particularly given you do have the inclusion of those gentlemen. has a high dividend. as i've pointed out over the long term, 20 years, it's still has been dead money. there have been great periods. ian reed did oversee a decent move in the stock. ultimately, you're not really talking about much. a lot of that is today. basically the stock is flat. >> i think it's gone from 41 to 29 since bourla took over. it was hard to anticipate that we wouldn't be dependent on these covid vaccines in a way that was originally thought. that's fair. that was. >> i think they thought they had a longer tail. >> this was the new base of revenue. that's wh

>> albert bourla, who's dealing with an activist, who i talked to last week, although not completely exactly what he wants, jeff smith at pfizer. >> moderna's problem has to do with execution. pfizer's problem has to do with execution. the government's problem has to do with execution. what? >> nothing. i mean, we'll be talking about these numbers for quite some time. >> especially because it will be a contested election. do you intend to stay right here for the next seven weeks? carl will be doing night coverage, which will then extend to -- can they push that back and go to the march inauguration? >> maybe we'll have elon musk become king and that will take care of it. >> it would make sense in this oligarch era we're now in. >> he's the richest man in the world, he should be the king. why not? >> is the king ceremonial or does the king have powers? >> it's unclear to me. >> what do you think the king's speech would be like? >> show got weird there for a second. more "squawk on the street" in a minute. your record label is taking off. but so is your sound engineer. you need to hire

albert bourla also received calls from the group. >>> and the decision to take eli lilly's blockbustereight loss and diabetes drugs off the lists of medicines in short supply last week. compounding ingredients and federal regulations allow compounded versions to be sold to meet demand if a drug is in short fsupply. the lawsuit said the public did not get a chance to weigh in on its decision and trusted assurances from eli lilly about demand. lilly is self interested in monopolizing the industry. >>> the u.s. judge issued a permanent injunction to force google to offer alternatives for the play store. google well be restricted from sharing fees to compete. this stems from epic games against google and anti-competitive practices. both google and apple app store takes 30%. this will allow developers to keep more of the revenue bypassing the google rules or fees and in some ways, dpgoogle in a tougher place than apple. the truth is they had ways to side load and other things and different apps all the time. >>> we've got pepsi shares out with earnings right now. pepsi came in with earnings